DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Comment by Cmonalreadyon Feb 15, 2013 8:00pm

276 Views

Post# 20998713

RE: RE: RE: RE: RE: RE: RE: More

Just saying we have all been sold a bill of goods here. We either heard it from someone or expected the stock price to jump in the last 3-4 months. Instead the phase 2 comes out and there is no reaction or volume. I have the feeling someone spread some news so they could generate some volume at a decent level to liquidate some of their position. I could be wrong but the stock has not done what I was told it would do. So "not as it seems"

Bullboard Posts

Mullen Group: Navigates market challenges towards success